COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Europäisches Patentamt - (2018) vom: 28. Sept. Zur Gesamtaufnahme - year:2018 |
|---|
| Sprache: |
Unbestimmt |
|---|
| Beteiligte Personen: |
CAO JIANGUO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2018-09-28, Last updated: 2021-03-11 |
|---|
| Patentnummer: |
US2012071516 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA00719966X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA00719966X | ||
| 003 | DE-627 | ||
| 005 | 20230504080359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2018 xx |||||o 00| ||und c | ||
| 035 | |a (DE-627)EPA00719966X | ||
| 035 | |a (EPA)US2012071516 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a und | ||
| 100 | 0 | |a CAO JIANGUO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2018-09-28, Last updated: 2021-03-11 | ||
| 520 | |a Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | ||
| 650 | 4 | |a C07D | |
| 650 | 4 | |a A61K | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61P | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a WHITTEN JEFFREY P |e verfasserin |4 aut | |
| 700 | 0 | |a PEI YAZHONG |e verfasserin |4 aut | |
| 700 | 0 | |a WANG ZHIJUN |e verfasserin |4 aut | |
| 700 | 0 | |a ROGERS EVAN |e verfasserin |4 aut | |
| 700 | 0 | |a GREY JONATHAN |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2018) vom: 28. Sept. |
| 773 | 1 | 8 | |g year:2018 |g day:28 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/searchResults?DB=EPODOC&locale=en_EP&query=US2012071516A1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2018 |b 28 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2018 |b 28 |c 09 | ||